PD-L1 Inhibitor
RAI + Immunotherapy for Thyroid Cancer
Recruiting1 awardPhase < 1
Basking Ridge, New Jersey
This trial is testing a new drug, durvalumab, to see if it can help treat thyroid cancer. Durvalumab blocks a protein that can be present on tumor and normal cells, which may help the immune system fight the cancer.
18F-TFB PET Imaging for Thyroid Cancer
Recruiting1 award8 criteria
New York, New York
This trial is testing a new scan that can quickly show how much radioactive iodine thyroid cancer will absorb. It aims to help doctors plan treatment more effectively without interfering with the therapy. The study focuses on patients with thyroid cancer to improve their treatment outcomes.
Alkylating agents
Cyclophosphamide + Sirolimus for Advanced Thyroid Cancer
Recruiting1 awardPhase 2
Ann Arbor, Michigan
This trial uses two drugs, Cyclophosphamide and Sirolimus, to treat patients with thyroid cancer that has spread. Cyclophosphamide kills cancer cells by breaking their DNA, while Sirolimus stops them from growing. Sirolimus has been used in various treatments and has shown effectiveness against different cancers. Patients are monitored for side effects and effectiveness.
Popular Filters
Trials for Thyroid Cancer Patients
MEK Inhibitor
Trametinib for Thyroid Cancer
Recruiting1 awardPhase 2
New York, New York
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
Recruiting1 awardPhase 1
New York, New York
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
Trials for Thyroid Gland Carcinoma Patients
MEK Inhibitor
Trametinib for Thyroid Cancer
Recruiting1 awardPhase 2
New York, New York
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
Recruiting1 awardPhase 1
New York, New York
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
Trials for BRAF Positive Patients
MEK Inhibitor
Trametinib for Thyroid Cancer
Recruiting1 awardPhase 2
New York, New York
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
Recruiting1 awardPhase 1
New York, New York
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Chemotherapy
Atezolizumab + Chemotherapy for Thyroid Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing a combination of atezolizumab and chemotherapy in patients with aggressive thyroid cancer. The treatment aims to boost the immune system and stop cancer cell growth. Atezolizumab helps enhance the immune response against cancer cells.
Radioactive Isotope
I-124 PET/CT Dosimetry for Thyroid Cancer
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is comparing the two methods of TSH stimulation (endogenous by thyroid hormone withdrawal leading to hypothyroidism and exogenous by injection of human recombinant TSH) in order to find the appropriate 131-I activity.
Phase 3 Trials
Vitamin D Analog
Paricalcitol for Secondary Hyperparathyroidism in Pediatric Kidney Disease
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing a medication called paricalcitol, which is taken by mouth, in young children with severe kidney disease and hormone imbalance. The goal is to see if it is safe and effective in balancing their hormone levels. Paricalcitol has been shown to be effective in reducing calcium and phosphorus levels in patients with kidney issues.
Kinase Inhibitor
Dabrafenib + Trametinib for Thyroid Cancer
Recruiting1 awardPhase 3
Edmonton, Alberta
This trial tests two drugs, dabrafenib and trametinib, on adults with a specific type of advanced thyroid cancer. These patients have a genetic mutation and have not responded to other treatments. The drugs work by blocking proteins that help cancer cells grow.
Trials With No Placebo
MEK Inhibitor
Trametinib for Thyroid Cancer
Recruiting1 awardPhase 2
New York, New York
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
Recruiting1 awardPhase 1
New York, New York
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.